IWGDF GUIDELINE RECOMMENDATION
The International Working Group on the Diabetic Foot (IWGDF) now recommends the use of 3C Patch® as an adjunctive treatment.49 The guideline recommendation is published in the new guidelines on The Prevention and Management of Diabetic Foot Disease.
The product is also CE marked in Europe. The intended use of the product is to produce an autologous platelet-rich fibrin for wound management of recalcitrant wounds.
3C Patch® will be the new name for Leucopatch® during 2019 in Europe.